ADP-520 / Adaptimmune - LARVOL DELTA

Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy (Frontiers) - "The phenotypic distribution, expansion and persistence of ADP-520 TRuC T cells were measured in vitro under autonomous and antigen-dependent conditions, with the contributions of TCR and IL-15 signaling pathways ascertained using inhibition assays. Chronic antigen stimulation was used to evaluate exhaustion-resistance, while anti-tumor potency was explored both in vitro and in vivo...ADP-520 was found to have potent and antigen-specific activity against hematological and solid CD70-expressing tumors, without apparent fratricide or killing of bystander T cells despite CD70 expression by activated lymphocytes."

Preclinical • Solid Tumor

Adaptimmune Provides Q4 and Full Year 2024 Business Update (Adaptimmune Press Release) - "Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026...Implemented additional cost reduction for the PRAME and CD70 programs. The Company anticipates this will generate an additional $75m to $100m in aggregate cost savings over the next 4 years."

FDA approval • FDA filing • Pricing • Oncology • Soft Tissue Sarcoma • Synovial Sarcoma

Adaptimmune Reports Q2 2024 Financial and Business Updates (Adaptimmune Press Release) - "Adaptimmune Therapeutics plc...reports financial results and business updates for the second quarter ended June 30, 2024...Sarcoma centers of excellence across the Unites States are being onboarded as Authorized Treatment Centers (ATCs) for Tecelra...Uza-cel is being investigated in the SURPASS-3 Phase 2 clinical trial (NCT05601752) for the treatment of platinum-resistant ovarian cancer...The SURPASS-3 trial is currently enrolling patients; Screening in the SURPASS Phase 1 trial has stopped and enrolment will cease shortly....IND-enabling activities continue for ADP-600 (PRAME) and ADP-520 (CD70) programs."

Commercial • Enrollment status • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Synovial Sarcoma

TCR² Therapeutics Announces Pipeline Priorities for 2023 (GlobeNewswire) - "gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023. Second-generation enhanced programs TC-510 and TC-520 prioritized with TC-510 Phase 1 clinical trial ongoing and first meaningful objective response data expected in 2H 2023. Company to be streamlined with approximately 40 percent reduction in workforce."

P1 data • P2 data • Gynecologic Cancers • Ovarian Cancer • Solid Tumor

TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) - "TCR2 initiated the Phase 1 dose escalation portion of the Phase 1/2 clinical trial of TC-510, its first enhanced mesothelin-targeted TRuC-T cell that co-expresses a PD-1:CD28 chimeric switch receptor. Enrollment is ongoing and the Company expects to report on initial safety, efficacy and translational data from at least one of the Phase 1 dose escalation cohorts of the Phase 1/2 clinical trial in the second half of 2022; Pipeline: Initiate IND-enabling studies for TC-520, an enhanced CD70 targeting TRuC-T cell program, in 2022."

P1/2 data • Oncology • Solid Tumor

TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) - "Anticipated Milestones: Gavo-cel: Present the expanded Phase 1 dataset for gavo-cel in July 2022."

Preclinical • Oncology

TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy (GlobeNewswire) - "TCR2 Therapeutics Inc...announced the e-poster presentation of new preclinical data at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy, taking place October 5-6, 2021. The e-poster titled 'Expression of an IL-15 Receptor Fusion Protein Enhances the Persistence of TRuC-T Cells' highlights preclinical data on the Company’s proprietary mesothelin-directed T Cell Receptor Fusion Construct (TRuC®) T cells that express IL-15-based enhancements as a strategy for improving T cell persistence....In a mesothelioma xenograft mouse model, IL-15 co-expression resulted in a higher number of TRuC-T cells in the tumor and significantly increased their persistence in peripheral blood."

Preclinical • Lung Cancer • Mesothelioma • Oncology • Solid Tumor